Previous 10 | Next 10 |
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced its submission of a Marketing Authorization Application ( ...
After nearly 15 years of struggle, Reata has a PDUFA date of Feb 25 for Bardoxolone. The FDA raised four issues with the NDA, which will need to be addressed in an advisory committee meeting. The company is flush with cash and trading near 52-week lows. For further details s...
Reata Pharmaceuticals, Inc . (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that abstracts highlighting clinical data for bardoxolone methyl (“bardoxolone”) and dis...
Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...
Stanley Druckenmiller’s 13F portfolio value decreased from $3.89B to $3.48B this quarter. Duquesne added Netflix & Airbnb and increased Alphabet & Carvana while reducing Sea Limited and dropping Citigroup. The top three positions are at ~29% of the portfolio. ...
Reata Pharmaceuticals (NASDAQ: RETA) was having a terrible Tuesday, with its stock trading down by nearly 17% in late afternoon action. It scored earnings beats in its second quarter, but there was one notable cause for concern. After market hours on Monday, Reata published its ...
Gainers: Fulcrum Therapeutics (NASDAQ:FULC) +123%. Lightning eMotors (NYSE:ZEV) +52%. 3D Systems (NYSE:DDD) +41%. MediaCo (NASDAQ:MDIA) +40%. Allied Healthcare Products (NASDAQ:AHPI) +27%. Exagen (NASDAQ:XGN) +26%. IMV (NASDAQ:IMV) +23%. Arcturus Therapeutics (NASDAQ:ARCT) +21%. Orphazyme A/S...
Earnings news remained a key theme during Tuesday's midday trading. Squarespace (NYSE:SQSP) and Oak Street Health (NYSE:OSH) both dropped following the release of their quarterly updates. Meanwhile, Turning Point Therapeutics (NASDAQ:TPTX) got a boost after it reported better-than-expected re...
Gainers: Fulcrum Therapeutics (NASDAQ:FULC) +84%, Allied Healthcare Products (NASDAQ:AHPI) +39%, IMV (NASDAQ:IMV) +29%, Exagen (NASDAQ:XGN) +26%, Myomo (NYSE:MYO) +22%. Losers: SmileDirectClub (NASDAQ:SDC) -23%, EyeGate Pharmaceutica...
The following slide deck was published by Reata Pharmaceuticals, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Reata Pharmaceuticals, Inc. 2021 Q2 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS ® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (N...